News

Find News

Filter articles

Showing 31 to 40 of 3276 results

A deep dive into Regeneron v Kymab

US08-03-2021Alex Baldwin

On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.

CPI receives £5m from UK govt for 'vaccine library'

UK04-03-2021Alex Baldwin

UK innovation hub CPI has received a further £5 million investment from the UK government to support the development of new mRNA vaccines to protect against new variants of COVID-19.

GSK avoids $57m damages award over royalties

US04-03-2021Muireann Bolger

GlaxoSmithKline has avoided paying $57 million in damages after a US supreme court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug.

Senator calls on Biden to reject COVID IP waiver

02-03-2021Alex Baldwin

Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.

Puma and CANBridge cancel licensing deal for $20m

International02-03-2021Rory O'Neill

Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.

India calls for IP waiver to combat COVID-19

India02-03-2021Alex Baldwin

The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.

Five minutes with… Eva Kabir

International02-03-2021Alex Baldwin

Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

Cutting back the thickets of Biosimilars

International01-03-2021Alex Baldwin

The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally.

BGI secures appeal trial over Illumina DNA verdict

UK25-02-2021Alex Baldwin

Chinese genome sequencing company BGI has been given the go-ahead to appeal an English High Court ruling in an ongoing lawsuit launched by competitor Illumina regarding its DNA sequencing patents.

Five minutes with… Irena Royzman

International25-02-2021Alex Baldwin

Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

Showing 31 to 40 of 3276 results

LSIPR